MXCT Logo

MaxCyte, Inc. (MXCT) Stock Forecast & Price Prediction

Live MXCT Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Medical Devices

$4.36

-0.03 (-0.68%)

12 Month Price Forecast For MXCT

$4.36
Current Price
$462.10M
Market Cap
7 Ratings
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to MXCT Price Forecasts

+152.3%
To High Target of $11.00
+117.9%
To Median Target of $9.50
+60.6%
To Low Target of $7.00

MXCT Price Momentum

-3.1%
1 Week Change
-0.9%
1 Month Change
-10.8%
1 Year Change
+4.8%
Year-to-Date Change
-17.1%
From 52W High of $5.26
+37.8%
From 52W Low of $3.17

๐Ÿค” Considering MaxCyte (MXCT)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 4:20 AM UTC

MXCT Analyst Ratings & Price Targets

Based on our analysis of 4 Wall Street analysts, MXCT has a bullish consensus with a median price target of $9.50 (ranging from $7.00 to $11.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $4.36, the median forecast implies a 117.9% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Jacob Johnson at Stephens & Co., projecting a 152.3% upside. Conversely, the most conservative target is provided by Matt Hewitt at Craig-Hallum, suggesting a 60.6% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MXCT Analyst Consensus

7
Buy
0
Hold
0
Sell

MXCT Price Target Range

Low
$7.00
Average
$9.50
High
$11.00
Current: $4.36

Latest MXCT Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MXCT.

Date Firm Analyst Rating Change Price Target
Apr 23, 2024 Stephens & Co. Jacob Johnson Overweight Reiterates $11.00
Mar 13, 2024 BTIG Mark Massaro Buy Maintains $8.00
Mar 13, 2024 Stephens & Co. Jacob Johnson Overweight Reiterates $11.00
Nov 29, 2023 Craig-Hallum Matt Hewitt Buy Initiates $7.00
Oct 5, 2023 Stephens & Co. Jacob Johnson Overweight Reiterates $12.00
Mar 28, 2023 Stephens & Co. Jacob Johnson Overweight Reiterates $12.00
Aug 15, 2022 BTIG Mark Massaro Buy Maintains $11.00
Aug 24, 2021 Stifel Buy Initiates $0.00
Aug 24, 2021 William Blair Outperform Initiates $0.00
Aug 24, 2021 Cowen & Co. Outperform Initiates $0.00
Aug 24, 2021 BTIG Buy Initiates $0.00
Aug 24, 2021 Stephens & Co. Overweight Initiates $0.00

Stocks Similar to MaxCyte, Inc.

The following stocks are similar to MaxCyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

MaxCyte, Inc. (MXCT) Financial Data

MaxCyte, Inc. has a market capitalization of $462.10M with a P/E ratio of -11.6x. The company generates $45.60M in trailing twelve-month revenue with a -78.4% profit margin.

Revenue growth is +2.0% quarter-over-quarter, while maintaining an operating margin of -172.1% and return on equity of -16.0%.

Valuation Metrics

Market Cap $462.10M
Enterprise Value $327.56M
P/E Ratio -11.6x
PEG Ratio -10.9x
Price/Sales 10.1x

Growth & Margins

Revenue Growth (YoY) +2.0%
Gross Margin +76.4%
Operating Margin -172.1%
Net Margin -78.4%
EPS Growth +2.0%

Financial Health

Cash/Price Ratio +33.4%
Current Ratio 9.8x
Debt/Equity 8.6x
ROE -16.0%
ROA -11.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

MaxCyte, Inc. logo

MaxCyte, Inc. (MXCT) Company Overview

About MaxCyte, Inc.

What They Do

Develops next-generation cell therapies and technologies.

Business Model

The company generates revenue by licensing and selling its innovative instruments and technologies for cell transfection and therapy development. It also provides disposable processing assemblies and consumables to pharmaceutical and biotechnology companies, supporting their drug discovery and bio-manufacturing needs.

Additional Information

Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte, Inc. operates in both U.S. and international markets, positioning itself in the growing field of cell therapies with a broad range of products aimed at enhancing drug development processes.

Company Information

Sector

Healthcare

Industry

Medical Devices

Employees

143

CEO

Mr. Maher Masoud

Country

United States

IPO Year

N/A

MaxCyte, Inc. (MXCT) Latest News & Analysis

MXCT stock latest news image
Quick Summary

MaxCyte, Inc. (NASDAQ: MXCT) will release its Q4 and full year 2024 financial results on March 11, 2025, after market close, followed by a conference call at 4:30 p.m. ET.

Why It Matters

MaxCyte's upcoming financial results release could impact its stock price, reflecting investor sentiment on the company's performance and future prospects in the cell therapeutics market.

Source: GlobeNewsWire
Market Sentiment: Neutral
MXCT stock latest news image
Quick Summary

MaxCyte, Inc. (Nasdaq: MXCT) has acquired SeQure Dx, a leader in editing assessment services for cell and gene therapies, enhancing its cell-engineering solutions.

Why It Matters

MaxCyte's acquisition of SeQure Dx enhances its capabilities in cell and gene therapies, potentially increasing its market position and driving future revenue growth.

Source: GlobeNewsWire
Market Sentiment: Neutral
MXCT stock latest news image
Quick Summary

Glancy Prongay & Murray LLP is investigating MaxCyte, Inc. (NASDAQ: MXCT) for potential violations of state laws by the company and its executives. Investors can contact GPM for more information.

Why It Matters

Investigations into potential legal violations can lead to stock volatility and impact investor confidence, affecting MaxCyte's market performance and future valuations.

Source: Business Wire
Market Sentiment: Neutral
MXCT stock latest news image
Quick Summary

MaxCyte Inc. (NASDAQ: MXCT) develops technology for next-generation cell and gene therapies, playing a key role in the advancement of cell therapies globally.

Why It Matters

MaxCyte's role in cell and gene therapies positions it at the forefront of biotechnological innovation, potentially driving growth and attracting investor interest in a rapidly expanding market.

Source: MarketBeat
Market Sentiment: Neutral
MXCT stock latest news image
Quick Summary

MaxCyte (MXCT) is identified as a stock with strong recent price performance, making it a potential candidate for investors seeking upward-trending stocks.

Why It Matters

MaxCyte's recent price strength indicates solid momentum, suggesting potential for continued gains, which may attract investors seeking growth opportunities.

Source: Zacks Investment Research
Market Sentiment: Positive
MXCT stock latest news image
Quick Summary

MaxCyte (MXCT) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects, which may lead to a rise in stock prices.

Why It Matters

MaxCyte's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving the stock price upward in the near term.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About MXCT Stock

What is MaxCyte, Inc.'s (MXCT) stock forecast for 2025?

Based on our analysis of 4 Wall Street analysts, MaxCyte, Inc. (MXCT) has a median price target of $9.50. The highest price target is $11.00 and the lowest is $7.00.

Is MXCT stock a good investment in 2025?

According to current analyst ratings, MXCT has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.36. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MXCT stock?

Wall Street analysts predict MXCT stock could reach $9.50 in the next 12 months. This represents a 117.9% increase from the current price of $4.36. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is MaxCyte, Inc.'s business model?

The company generates revenue by licensing and selling its innovative instruments and technologies for cell transfection and therapy development. It also provides disposable processing assemblies and consumables to pharmaceutical and biotechnology companies, supporting their drug discovery and bio-manufacturing needs.

What is the highest forecasted price for MXCT MaxCyte, Inc.?

The highest price target for MXCT is $11.00 from Jacob Johnson at Stephens & Co., which represents a 152.3% increase from the current price of $4.36.

What is the lowest forecasted price for MXCT MaxCyte, Inc.?

The lowest price target for MXCT is $7.00 from Matt Hewitt at Craig-Hallum, which represents a 60.6% increase from the current price of $4.36.

What is the overall MXCT consensus from analysts for MaxCyte, Inc.?

The overall analyst consensus for MXCT is bullish. Out of 4 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.50.

How accurate are MXCT stock price projections?

Stock price projections, including those for MaxCyte, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.